Department of Nephrology and Dialysis, NephroCare-ASST Bergamo-Est, Bolognini Hospital, Seriate, Italy.
Fresenius Medical Care Deutschland GmbH, Clinical and Epidemiological Research, Bad Homburg, Germany.
PLoS One. 2019 Feb 22;14(2):e0212795. doi: 10.1371/journal.pone.0212795. eCollection 2019.
Anemia is a major comorbidity of patients with end-stage renal disease and poses an enormous economic burden to health-care systems. High dose erythropoiesis-stimulating agents (ESAs) have been associated with unfavorable clinical outcomes. We explored whether mixed-dilution hemodiafiltration (Mixed-HDF), based on its innovative substitution modality, may improve anemia outcomes compared to the traditional post-dilution hemodiafiltration (Post-HDF).
We included 174 adult prevalent dialysis patients (87 on Mixed-HDF, 87 on Post-HDF) treated in 24 NephroCare dialysis centers between January 2010 and August 2016 into this retrospective cohort study. All patients were dialyzed three times per week and had fistula/graft as vascular access. Patients were matched at baseline and followed over a one-year period. The courses of hemoglobin levels (Hb) and monthly ESA consumption were compared between the two groups with linear mixed models.
Mean baseline Hb was 11.9±1.3 and 11.8±1.1g/dl in patients on Mixed- and Post-HDF, respectively. While Hb remained stable in patients on Mixed-HDF, it decreased slightly in patients on Post-HDF (at month 12: 11.8±1.2 vs 11.1±1.2g/dl). This tendency was confirmed by our linear mixed model (p = 0.0514 for treatment x time interaction). Baseline median ESA consumption was 6000 [Q1:0;Q3:16000] IU/4 weeks in both groups. Throughout the observation period ESA doses tended to be lower in the Mixed-HDF group (4000 [Q1:0;Q3:16000] vs 8000 [Q1:0;Q3:20000] IU/4 weeks at month 12; p = 0.0791 for treatment x time interaction). Sensitivity analyses, adjusting for differences not covered by matching at baseline, strengthened our results (Hb: p = 0.0124; ESA: p = 0.0687).
Results of our explorative study suggest that patients on Mixed-HDF may have clinical benefits in terms of anemia management. This may also have a beneficial economic impact. Future studies are needed to confirm our hypothesis-generating results and to provide additional evidence on the potential beneficial effects of Mixed-HDF.
贫血是终末期肾病患者的主要合并症,给医疗保健系统带来了巨大的经济负担。高剂量促红细胞生成素刺激剂(ESA)与不良的临床结局相关。我们探讨了基于创新替代方式的混合稀释血液透析滤过(Mixed-HDF)是否可能改善贫血结局,与传统的后稀释血液透析滤过(Post-HDF)相比。
我们将 2010 年 1 月至 2016 年 8 月期间在 24 个 NephroCare 透析中心接受治疗的 174 名成年透析患者(Mixed-HDF 组 87 名,Post-HDF 组 87 名)纳入本回顾性队列研究。所有患者每周透析 3 次,均使用瘘管/移植物作为血管通路。根据基线进行匹配,并在一年的时间内进行随访。使用线性混合模型比较两组血红蛋白水平(Hb)和每月 ESA 消耗的变化。
Mixed-HDF 组和 Post-HDF 组患者的平均基线 Hb 分别为 11.9±1.3 和 11.8±1.1g/dl。在 Mixed-HDF 组中,Hb 保持稳定,而在 Post-HDF 组中略有下降(在第 12 个月时:11.8±1.2 vs 11.1±1.2g/dl)。线性混合模型证实了这一趋势(治疗 x 时间交互作用的 p = 0.0514)。两组患者的基线中位 ESA 剂量为 6000 [Q1:0;Q3:16000]IU/4 周。在整个观察期间,Mixed-HDF 组的 ESA 剂量趋于较低(第 12 个月时为 4000 [Q1:0;Q3:16000] vs 8000 [Q1:0;Q3:20000]IU/4 周;p = 0.0791 用于治疗 x 时间交互作用)。调整基线未涵盖的差异的敏感性分析加强了我们的结果(Hb:p = 0.0124;ESA:p = 0.0687)。
我们的探索性研究结果表明,接受 Mixed-HDF 治疗的患者在贫血管理方面可能具有临床益处。这也可能产生有益的经济影响。需要进一步的研究来证实我们的假设生成结果,并提供关于 Mixed-HDF 潜在有益效果的额外证据。